Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma

Liu,Zhaoyun; Liu,Hui; Li,Yanqi; Wang,Yangyang; Xing,Rui; Mi,Fu; Xiang,Chenhuan; Fu,Rong

doi:10.3892/ijmm.2020.4475

Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma

Authors:
- Zhaoyun Liu
- Hui Liu
- Yanqi Li
- Yangyang Wang
- Rui Xing
- Fu Mi
- Chenhuan Xiang
- Rong Fu
View Affiliations

Affiliations: Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: January 24, 2020 https://doi.org/10.3892/ijmm.2020.4475
Pages: 1112-1120
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study sought to investigate the correlation between adipose cytokines (visfatin, leptin and adiponectin) and markers of multiple myeloma bone disease, and to determine the effects and mechanism of action of adiponectin on the differentiation and maturation of osteoclasts in multiple myeloma (MM). The levels of visfatin, leptin and adiponectin were measured. Their association with the indices of myeloma tumor load and bone disease were analyzed. Reverse transcription‑quantitative PCR was used to detect the expression of receptor activator of nuclear factor‑κB ligand (RANKL), osteoclast associated Ig‑like receptor (OSCAR), tartrate‑resistant acid phosphatase (TRAP) and Cathepsin K genes. Flow cytometry was used to detect the expression of adiponectin receptor 1 (AdipoR1) and the phosphorylation of the mechanistic target of rapamycin kinase (mTOR) pathway‑associated proteins mTOR and eukaryotic translation initiation factor 4E‑binding protein (4EBP1). There were no significant correlations among leptin, visfatin and the indexes of myeloma tumor load and bone disease. Serum adiponectin levels were significantly lower in patients with newly diagnosed multiple myeloma compared with healthy volunteers (12.37±3.13 vs. 13.80±0.95; P<0.05). The number of mature osteoclasts in the adiponectin group was lower compared with in the control group. Adiponectin also inhibited the mRNA expression of the osteoclast‑associated factors RANKL, OSCAR, TRAP and Cathepsin K. Comparison between the non‑adiponectin group and the adiponectin group revealed that adiponectin increased the expression of AdipoR1 on the surface of osteoclast precursor cells (26.21±4.27% vs. 29.86±6.23%; P<0.05) and reduced the expression of phosphorylated (p‑)mTOR (7.89±1.00% vs. 5.91±1.26%; P<0.05) and p‑4EBP1 (26.78±5.00% vs. 22.49±4.24%; P<0.05). The p‑mTOR and p‑4EBP1 levels in the adiponectin + MHY1485 (an mTOR signaling pathway‑specific agonist) group were significantly higher compared with those in the adiponectin group. It was revealed that adiponectin may inhibit osteoclast differentiation and maturation via the mTOR pathway. In conclusion, adiponectin inhibits the differentiation and maturation of osteoclasts by increasing the expression of AdipoR1 and reducing the phosphorylation levels of mTOR and 4EBP1 in patients with MM.

View Figures

View References

1	Palumbo A and Anderson K: Multiple myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
2	Aparicio T, Kotelevets L, Tsocas A, Laigneau JP, Sobhani I, Chastre E and Lehy T: Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut. 54:1136–1145. 2005. View Article : Google Scholar : PubMed/NCBI
3	Jardé T, Caldefie-Chézet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, Guillot J and Vasson MP: Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 53:484–487. 2008. View Article : Google Scholar : PubMed/NCBI
4	Fenton JI, Birmingham JM, Hursting SD and Hord NG: Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer. 122:2437–2445. 2008. View Article : Google Scholar : PubMed/NCBI
5	Mohammadi M, Zarghami N, Hedayati M, Ghaemmaghami S, Yamchi RM and Mohaddes M: Visfatin effects on telomerase gene expression in AGS gastric cancer cell line. Indian J Cancer. 52:32–35. 2015. View Article : Google Scholar
6	Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N and Purdue MP: A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 120:4418–4420. 2012. View Article : Google Scholar : PubMed/NCBI
7	Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV and Oyajobi BO: PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia. 28:2080–2089. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR and Edwards CM: Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 118:5872–5882. 2011. View Article : Google Scholar : PubMed/NCBI
9	Teitelbaum SL and Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet. 4:638–649. 2003. View Article : Google Scholar : PubMed/NCBI
10	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
11	Massey HM and Flanagan AM: Human osteoclasts derive from CD14-positive monocytes. Br J Haematol. 106:167–170. 1999. View Article : Google Scholar : PubMed/NCBI
12	Kim MS, Day CJ and Morrison NA: MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 280:16163–16169. 2005. View Article : Google Scholar : PubMed/NCBI
13	Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, et al: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 423:762–769. 2003. View Article : Google Scholar : PubMed/NCBI
14	Pacheco-Pantoja EL, Waring VJ, Wilson PJ, Fraser WD and Gallagher JA: Adiponectin receptors are present in RANK-L-induced multinucleated osteoclast-like cells. J Recept Signal Transduct Res. 33:291–297. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC and Martin SK: The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 94:343–354. 2015. View Article : Google Scholar
16	Walker S, Wankell M, Ho V, White R, Deo N, Devine C, Dewdney B, Bhathal P, Govaere O, Roskams T, et al: Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. PLoS One. 14:e02128602019. View Article : Google Scholar : PubMed/NCBI
17	Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, et al: Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood. 117:4691–4695. 2011. View Article : Google Scholar : PubMed/NCBI
18	Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM and Rahemtulla A: Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer. 3:455–457. 2003. View Article : Google Scholar
19	Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
20	Warhurst G, Dunn G, Chadwick P, Blackwood B, McAuley D, Perkins GD, McMullan R, Gates S, Bentley A, Young D, et al: Rapid detection of health-care-associated bloodstream infection in critical care using multipathogen real-time polymerase chain reaction technology: A diagnostic accuracy study and systematic review. Health Technol Assess. 19:1–142. 2015. View Article : Google Scholar : PubMed/NCBI
21	Sonzogni-Desautels K, Di Lenardo TZ, Renteria AE, Gascon MA, Geary TG and Ndao M: A protocol to count crypto-sporidium oocysts by flow cytometry without antibody staining. PLoS Negl Trop Dis. 13:e00072592019. View Article : Google Scholar
22	Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH and Karsdal MA: Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab. 25:36–45. 2007. View Article : Google Scholar
23	Tong X, Gu J, Song R, Wang D, Sun Z, Sui C, Zhang C, Liu X, Bian J and Liu Z: Osteoprotegerin inhibit osteoclast differentiation and bone resorption by enhancing autophagy via AMPK/mTOR/p70S6K signaling pathway in vitro. J Cell Biochem. 6:274682018.
24	Birmann BM, Giovannucci E, Rosner B, Anderson KC and Colditz GA: Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 16:1474–1478. 2007. View Article : Google Scholar : PubMed/NCBI
25	Morris EV and Edwards CM: Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma. J Cell Physiol. 233:9159–9166. 2018. View Article : Google Scholar : PubMed/NCBI
26	Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, Waage A and Iversen PO: Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol. 83:460–470. 2009. View Article : Google Scholar : PubMed/NCBI
27	Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U and Reseland JE: Adiponectin and its receptors are expressed in bone-forming cells. Bone. 35:842–849. 2004. View Article : Google Scholar : PubMed/NCBI
28	Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, Lekka A and Mantzoros CS: Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: A case-control study. Cancer Causes Control. 20:193–199. 2009. View Article : Google Scholar
29	Peng F, Fu R, Liu H, Wang Y, Ding K, Ding S, Liu Z, Ruan E, Qu W, Wang H, et al: Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease. Zhonghua Yi Xue Za Zhi. 95:3436–3439. 2015.In Chinese.
30	Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T and Kanis JA: International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 49:1271–1274. 2011. View Article : Google Scholar : PubMed/NCBI
31	Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, et al: The use of biochemical markers of bone remodeling in multiple myeloma: A report of the international myeloma working group. Leukemia. 24:1700–1712. 2010. View Article : Google Scholar : PubMed/NCBI
32	Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H and Shimomura I: Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 331:520–526. 2005. View Article : Google Scholar : PubMed/NCBI
33	Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K and Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116:1784–1792. 2006. View Article : Google Scholar : PubMed/NCBI
34	Nakayama S, Miyoshi Y, Ishihara H and Noguchi S: Growth-Inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat. 112:405–410. 2008. View Article : Google Scholar
35	Ogawa T, Tokuda M, Tomizawa K, Matsui H, Itano T, Konishi R, Nagahata S and Hatase O: Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun. 249:226–230. 1998. View Article : Google Scholar : PubMed/NCBI
36	Viñals F, López-Rovira T, Rosa JL and Ventura F: Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett. 510:99–104. 2002. View Article : Google Scholar : PubMed/NCBI
37	Oldham S and Hafen E: Insulin/IGF and target of rapamycin signaling: A TOR de force in growth control. Trends Cell Biol. 13:79–85. 2003. View Article : Google Scholar : PubMed/NCBI
38	Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM and Cho YS: Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 19:557–568. 2010. View Article : Google Scholar
39	Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH and Kim HH: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 30:71–77. 2002. View Article : Google Scholar : PubMed/NCBI
40	Sugatani T and Hruska KA: Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 280:3583–3589. 2005. View Article : Google Scholar
41	Glantschnig H, Fisher JE, Wesolowski G, Rodan GA and Reszka AA: M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10:1165–1177. 2003. View Article : Google Scholar : PubMed/NCBI
42	Kloos B, Chakraborty S, Lindner SG, Noack K, Harre U, Schett G, Krämer OH and Kubatzky KF: Pasteurella multocida toxin-induced osteoclastogenesis requires mTOR activation. Cell Commun Signal. 13:402015. View Article : Google Scholar
43	Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, et al: Targeting bone metastatic cancer: Role of the mTOR pathway. Biochim Biophys Acta. 1845:248–254. 2014.PubMed/NCBI
44	Hadji P, Coleman R and Gnant M: Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 87:101–111. 2013. View Article : Google Scholar : PubMed/NCBI
45	Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, et al: Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 34:339–344. 2009.PubMed/NCBI